Roman Fabbricatore

Raed M. Al-Rajabi, MD, discussed the state of immune effector cell therapy for GI malignancies following a presentation he gave at the 2025 ICE-T Congress.

The safety profile of tucatinib plus trastuzumab and pertuzumab was consistent with the established profiles of each individual agent.

The most pronounced overall and recurrence-free survival benefit with chemoradiotherapy was observed among patients with TP53-abnormal endometrial cancer.

The addition of comprehensive bridging radiotherapy to extramedullary disease sites before CAR T therapy may improve PFS outcomes in multiple myeloma.

A manageable safety profile and survival benefit was observed across patient groups with somatostatin receptor–positive GEP-NETs.

Developers plan to discuss a regulatory path to conditional marketing authorization for OST-HER2 in the UK, US, and EU in resected metastatic osteosarcoma.

Imaging developments have made it possible to detect nodal recurrence at low PSA levels, which could help guide salvage approaches for prostate cancer.

Data from the phase 3 DESTINY-Breast09 trial presented at the 2025 ASCO Annual Meeting formed the basis of the supplemental NDA.

Cryoablation, when combined with adjuvant endocrine therapy, may offer a minimally invasive outpatient strategy in older patients with breast cancer.

The regulatory agency gave a PDUFA target action date of April 6, 2026, for Orca-T among patients with AML, ALL, and MDS.

The safety profile of dato-DXd was consistent with previous clinical trials assessing the agent in breast cancer.

RLT-based combinations, RLTs across genitourinary cancers, and RLTs in earlier lines of therapy are among the considerations for further research.

A study by the Blood and Marrow Transplant Clinical Trials Network found that a donor search prognosis strategy may move those with cancer to HCT faster.

Grade 2 or higher genitourinary acute toxicity was observed in 27.3% of patients treated with 2 fractions of SBRT vs 29.2% of patients treated with 5 fractions.

Treatment-related AEs with sunvozertinib were consistent with EGFR tyrosine kinase inhibitors in patients with NSCLC with EGFR exon 20 insertion mutations.

The decision is based on phase 3 DESTINY-Breast11 trial data, in which the investigational regimen displayed improved pCR vs SOC in this breast cancer population.

In the phase 3 EMBER-3 trial, Guardant360 CDx was used to identify patients with ESR1-mutated advanced breast cancer who may benefit from imlunestrant.

Biomarker research may better elucidate clinical benefit and identify mechanisms of resistance with tarlatamab in extensive-stage small cell lung cancer.

The efficacy of TTFields was greater among patients who received immune checkpoint inhibition for the treatment of brain metastatic NSCLC.

Artificial intelligence used in conjunction with clinicians may help standardize and expedite pathology workflows and reduce variability in TIL scoring.

No toxicity-related discontinuations were seen with adjuvant radiotherapy among patients with muscle-invasive bladder cancer.

The addition of certepetide to a FOLFIRINOX-based regimen was safe in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma.

Artificial intelligence can be used to automate genetic counseling processes and streamline a patient’s communication with relatives regarding genetic risk.

Black patients experienced lower survival rates across cancer types and several categories of urbanicity, particularly in breast and colorectal cancers.

In patients with ES-ECLC treated with chemotherapy and immunotherapy, stereotactic body radiation therapy did not significantly improve overall survival.

IMNN-001 exhibits prolonged favorable safety among patients with advanced newly diagnosed ovarian cancer.

The median PFS was not reached with daratumumab-lenalidomide maintenance after a median follow-up of 49 months in those with multiple myeloma.

No TRAEs leading to dose discontinuation, DLTs, or belantamab-related corneal events above grade 1 occurred with belantamab in multiple myeloma.

In patients with LS-SCLC who were ineligible for a prophylactic cranial irradiation, toripalimab appeared to decrease the progression of brain metastases.